Ascendis Pharma A/S (ASND) stock
ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 7/30
$275.39+8.32 (+3.12%)
Close on Nov 13, 2026Market cap $17.07BP/E 22.4Yield –
Ascendis Pharma A/S total assets
Total assets on the balance sheet at the end of each period.
Ascendis Pharma A/S's total assets was €2.29B at Jun 30, 2026. For fiscal 2025 it was €1.30B, up 10.4% from the year before. The highest annual figure on record is €1.30B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €1.30B | +10.4% |
| FY2024 | Dec 31, 2024 | €1.18B | +42.9% |
| FY2023 | Dec 31, 2023 | €825.59M | -24.2% |
| FY2022 | Dec 31, 2022 | €1.09B | +0.4% |
| FY2021 | Dec 31, 2021 | €1.08B | +10.7% |
| FY2020 | Dec 31, 2020 | €979.79M | +44.8% |
| FY2019 | Dec 31, 2019 | €676.73M | +112.2% |
| FY2018 | Dec 31, 2018 | €318.97M | +51.2% |
| FY2017 | Dec 31, 2017 | €210.98M | +11.0% |
| FY2016 | Dec 31, 2016 | €190.07M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €2.29B | +110.1% |
| Q1 FY2026 | Mar 31, 2026 | €2.00B | +88.7% |
| Q4 FY2025 | Dec 31, 2025 | €1.30B | +10.4% |
| Q3 FY2025 | Sep 30, 2025 | €1.15B | +5.6% |
| Q2 FY2025 | Jun 30, 2025 | €1.09B | +43.5% |
| Q1 FY2025 | Mar 31, 2025 | €1.06B | +32.3% |
| Q4 FY2024 | Dec 31, 2024 | €1.18B | +42.9% |
| Q3 FY2024 | Sep 30, 2024 | €1.09B | +25.3% |
| Q2 FY2024 | Jun 30, 2024 | €758.30M | -8.0% |
| Q1 FY2024 | Mar 31, 2024 | €802.50M | -16.9% |
| Q4 FY2023 | Dec 31, 2023 | €825.59M | -24.2% |
| Q3 FY2023 | Sep 30, 2023 | €873.21M | -31.4% |
| Q2 FY2023 | Jun 30, 2023 | €823.82M | -37.9% |
| Q1 FY2023 | Mar 31, 2023 | €966.27M | -29.8% |
| Q4 FY2022 | Dec 31, 2022 | €1.09B | +0.4% |
| Q3 FY2022 | Sep 30, 2022 | €1.27B | +5.7% |
| Q2 FY2022 | Jun 30, 2022 | €1.33B | +55.8% |
| Q1 FY2022 | Mar 31, 2022 | €1.38B | +42.7% |
| Q4 FY2021 | Dec 31, 2021 | €1.08B | +10.7% |
| Q3 FY2021 | Sep 30, 2021 | €1.21B | +15.2% |
| Q2 FY2021 | Jun 30, 2021 | €851.85M | +52.0% |
| Q1 FY2021 | Mar 31, 2021 | €965.31M | +55.3% |
| Q4 FY2020 | Dec 31, 2020 | €979.79M | +44.8% |
| Q3 FY2020 | Sep 30, 2020 | €1.05B | +42.3% |
| Q2 FY2020 | Jun 30, 2020 | €560.61M | -26.9% |
| Q1 FY2020 | Mar 31, 2020 | €621.41M | -18.4% |
| Q4 FY2019 | Dec 31, 2019 | €676.73M | +112.2% |
| Q3 FY2019 | Sep 30, 2019 | €734.96M | +119.2% |
| Q2 FY2019 | Jun 30, 2019 | €767.16M | +108.0% |
| Q1 FY2019 | Mar 31, 2019 | €761.94M | +108.8% |
| Q4 FY2018 | Dec 31, 2018 | €318.97M | +51.2% |
| Q3 FY2018 | Sep 30, 2018 | €335.23M | +76.4% |
| Q2 FY2018 | Jun 30, 2018 | €368.86M | – |
| Q1 FY2018 | Mar 31, 2018 | €364.83M | – |
| Q4 FY2017 | Dec 31, 2017 | €210.98M | – |
| Q4 FY2016 | Dec 31, 2016 | €190.07M | – |
See a number that looks wrong?